Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 15/20 | 0.67 |
| ▸ | JAK1 | P23458 | 3/20 | 0.67 |
| ▸ | AKT2 | P31751 | 2/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20582811 | 1.00 | JAK3 (0.67) | JAK3JAK1AKT2GSK3BKIT | |
| SCHEMBL15208683 | 1.00 | JAK3 (0.67) | JAK3JAK1AKT2GSK3BKIT | |
| SCHEMBL10169662 | 1.00 | JAK3 (0.67) | JAK3JAK1AKT2GSK3BKIT | |
| SCHEMBL10170240 | 1.00 | JAK3 (0.67) | JAK3JAK1AKT2GSK3BKIT | |
| SCHEMBL20125438 | 0.81 | JAK3 (0.95) | JAK3JAK1AKT2GSK3BKIT | |
| SCHEMBL16764926 | 0.77 | JAK3 (0.73) | JAK3JAK1AKT2GSK3BKIT | |
| SCHEMBL16764960 | 0.77 | JAK3 (0.73) | JAK3JAK1AKT2GSK3BKIT | |
| SCHEMBL20183418 | 0.74 | JAK3 (0.70) | JAK3JAK1AKT2GSK3BKIT | |
| SCHEMBL20183405 | 0.74 | JAK3 (0.70) | JAK3JAK1AKT2GSK3BKIT | |
| SCHEMBL15207751 | 0.74 | JAK3 (0.62) | JAK3JAK1AKT2DOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2629777-B1 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-12-19 | — | — | EP | disclosed |
| US-8937077-B2 | Bicyclic diamines as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937077-B2 | Bicyclic diamines as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-01-20 | — | — | US | disclosed |
| US-20130225577-A1 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-08-29 | — | — | US | disclosed |
| US-20130225577-A1 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-08-29 | — | — | US | disclosed |
| WO-2012054364-A2 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225577-A1 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | JAK3 3/4885JAK1 1/4885AKT2 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.